Northern Trust
ALXO icon

Northern Trust’s ALX Oncology ALXO Stock Holding History

Northern Trust’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.94M Buy
935,669
+798,705
+583% +$1.43M ﹤0.01% 3151
2026
Q1 		$275K Sell
136,964
-12,133
-8% -$23.1K ﹤0.01% 3837
2025
Q4 		$168K Buy
149,097
+53,937
+57% +$81.7K ﹤0.01% 4035
2025
Q3 		$174K Sell
95,160
-40,749
-30% -$35.3K ﹤0.01% 4022
2025
Q2 		$56.4K Sell
135,909
-182,274
-57% -$92K ﹤0.01% 4210
2025
Q1 		$198K Sell
318,183
-24,883
-7% -$29.9K ﹤0.01% 3949
2024
Q4 		$573K Buy
343,066
+23,324
+7% +$35.9K ﹤0.01% 3610
2024
Q3 		$582K Buy
319,742
+75,191
+31% +$280K ﹤0.01% 3537
2024
Q2 		$1.47M Sell
244,551
-661
-0.3% -$8.13K ﹤0.01% 3069
2024
Q1 		$2.73M Buy
245,212
+1,372
+0.6% +$19.3K ﹤0.01% 2804
2023
Q4 		$3.63M Buy
243,840
+52,316
+27% +$496K ﹤0.01% 2681
2023
Q3 		$919K Sell
191,524
-1,178
-0.6% -$6.39K ﹤0.01% 3328
2023
Q2 		$1.45M Sell
192,702
-5,855
-3% -$38.3K ﹤0.01% 3196
2023
Q1 		$897K Sell
198,557
-4,374
-2% -$33.1K ﹤0.01% 3252
2022
Q4 		$2.29M Sell
202,931
-86,836
-30% -$975K ﹤0.01% 2932
2022
Q3 		$2.77M Buy
289,767
+89,781
+45% +$1.05M ﹤0.01% 2831
2022
Q2 		$1.62M Buy
199,986
+26,292
+15% +$286K ﹤0.01% 3170
2022
Q1 		$2.94M Sell
173,694
-111
-0.1% -$1.9K ﹤0.01% 2891
2021
Q4 		$3.73M Sell
173,805
-859
-0.5% -$37.1K ﹤0.01% 2878
2021
Q3 		$12.9M Buy
174,664
+3,624
+2% +$242K ﹤0.01% 2097
2021
Q2 		$9.35M Sell
171,040
-5,010
-3% -$300K ﹤0.01% 2412
2021
Q1 		$13M Buy
176,050
+56,003
+47% +$4.41M ﹤0.01% 2124
2020
Q4 		$10.3M Buy
120,047
+4,231
+4% +$255K ﹤0.01% 2229
2020
Q3 		$4.37M Buy
+115,816
New +$4.55M ﹤0.01% 2629

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Northern Trust's ALXO Position: Q2 2026 in Review

Northern Trust increased its ALX Oncology (ALXO) stake by 583% in Q2 2026, buying an estimated $1.43M and bringing the position to 935,669 shares worth $1.94M. The position accounts for ﹤0.01% of the portfolio, ranked #3151.

Northern Trust first reported a position in ALXO in Q3 2020 and has held it in 24 quarters since. The position peaked at $13M in Q1 2021. 93 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

  • Northern Trust held 935,669 shares of ALX Oncology worth $1.94M as of Q2 2026.
  • Northern Trust bought 798,705 ALX Oncology shares in Q2 2026, an estimated $1.43M.
  • ALX Oncology made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #3151 holding.
  • Northern Trust first reported a position in ALX Oncology in Q3 2020 and has held it in 24 quarters since.
  • Northern Trust's ALX Oncology position peaked at $13M in Q1 2021.
  • 93 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.